<DOC>
	<DOCNO>NCT01929746</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetic ( PK ) profile BIIB019 ( Daclizumab High Yield Process ; DAC HYP ) administer single subcutaneous ( SC ) dose ( 75 mg 150 mg ) Japanese Caucasian adult healthy volunteer . The secondary objective study study population ass safety tolerability BIIB019 administer single SC dose ( 75 mg 150 mg ) .</brief_summary>
	<brief_title>Daclizumab Japanese PK Study</brief_title>
	<detailed_description />
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Key Japanese subject must bear Japan , parent grandparent Japanese origin , live outside Japan 5 year significantly modify diet since leave Japan . Subjects childbearing potential must practice effective contraception study willing able continue contraception least 4 month last dose study treatment . Body mass index ( BMI ) within 18 30 kg/m2 , inclusive . Nonsmoker willing abstain use tobacco tobaccocontaining product 24 hour prior clinic admission InClinic Period smoke 10 cigarette per day throughout remainder study . Must willing refrain alcohol consumption 48 hour prior Day 1 InClinic Period limit intake alcohol 2 unit per day throughout remainder study . Key History positive test result human immunodeficiency virus ( HIV ) antibody . History hepatitis positive test result hepatitis C virus antibody ( HCVAb ) hepatitis B virus antibody ( test hepatitis B surface antigen [ HBsAg ] and/or hepatitis B core antibody [ HBcAb ] ) . History tuberculosis ( TB ) positive QuantiFERONÂ®TB Gold test . There must clinical evidence TB physical examination subject . Note : Subjects prior adequate prophylaxis treatment latent TB appropriate course isoniazid equivalent , per country standard , exclude study participation . Subjects history carcinoma situ malignant disease , exception basal cell carcinoma completely excise prior study , eligible . Treatment prescription medication within 2 week Day 1 exception oral contraceptive woman childbearing potential . Treatment nonprescription medicinal product ( include vitamin/mineral/herbalcontaining preparation exclude acetaminophen ) within 7 day prior study treatment . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>